NL-OMON30290已完成3 期
Mycophenolate sodium (Myfortic) in the Treatment of Uveitis: a Pilot Study. - Myfortic in Uveitis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •patients with steroid refractory non-infectious uveitis
排除标准
- •1. fundus not visualizable opacities.
- •2. requiring ocular surgery < 3 months of treatment, or surgery in the prior 3 months.
- •3. pregnancy , nursing, or planning pregnancy within 6 months after screening (i.e., approximately 6 weeks following last treatment).
- •4. Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
- •5. History of systemic immunosuppressive therapy, other than steroids for ocular disease.
- •6. Creatinine clearance of < 20ml/min.
- •7. Patients with known hypersensitivity to prednisone, cyclosporine, Myfortic® or to drugs with similar chemical structures.
- •8. Patients with any clinically significant infection.
- •9. Documented HIV infection.
- •10. Patients with active TB or evidence of latent TB.
- •11. Patients with opportunistic infections, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, Aspergillosis, Histoplasmosis or atypical mycobacterium infection, etc, within the previous 6 months.
- •12. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
- •13. Presence of a transplanted organ (with the exception of a corneal transplant 3 months prior to screening).
- •14. Malignancy within the past 5 years (except for treated squamous or basal cell carcinoma of the skin without evidence of recurrence).
- •15. History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
- •16. Known recent substance abuse (drugs or alcohol).
- •17. Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.
- •18. Recent live vaccinations
- •19. Lues infection or serology
研究者
相似试验
进行中（未招募）
不适用
Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study. - Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study.EUCTR2006-004709-24-NLErasmusMC
招募中
不适用
Myfortic in uveitis.veitis.NL-OMON23540JAM van Laar, ErasmusMC24
进行中（未招募）
1 期
Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trialnon-infectious uveitisMedDRA version: 14.1Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2009-009998-10-DECentre for Ophthalmology, University of Tuebingen144
已完成
不适用
Mycophenolate mofetil treatment in a patient with frequently relapsing nephrotic syndromefrequently relapsing nephrotic syndromeJPRN-UMIN000007511Kumamoto University, Faculty of Life Sciences, Department of Pediatrics1
进行中（未招募）
不适用
Einsatz von Mycophenolsäure (Myfortic?) bei antikörpervermittelten immunologischen Erkrankungen: Effekt auf Krankheitsverlauf und Organfunktionsparameter - Myfortic bei immunologischen ErkrankungeEs werden Vaskulitiden und anktikörpervermittelten autoimmune Erkrankungen mit renaler, kutaner, neuraler oder endokriner Manifestation untersuchtEUCTR2006-003115-49-DETechnical University of Munich30